. 2023 Jan 6;145(2):1236–1246. doi: 10.1021/jacs.2c11111

Table 5. Half Inhibitory (IC₅₀) Values of 2, 3, or 4 in MDA-MB-231 or HCC38 Breast Cancer, HCT116 Colorectal Carcinoma, T24 Bladder Cancer Cell Lines, or the MCF10A Non-Tumorigenic Epithelial Cell Line (72 h Treatment)^a.

complex	MDA-MB-231	HCC38	HCT116	T24	MCF10A
cisplatin	32.5 ± 11.7	4.5 ± 0.3	5.0 ± 1.4	1.5 ± 0.5	26.5 ± 8.2
2	>100	>100	53.7 ± 9.9	34.4 ± 3.3	>100
3	21.8 ± 2.9	3.8 ± 2.5	16.4 ± 1.4	28.0 ± 4.4	>100
4	20.5 ± 9.6	16.5 ± 4.2	9.9 ± 1.8	29.9 ± 2.3	63.1 ± 21.0

Cisplatin treatment is included for comparison. Data are mean ± SD of three independent experiments.

Table 5. Half Inhibitory (IC50) Values of 2, 3, or 4 in MDA-MB-231 or HCC38 Breast Cancer, HCT116 Colorectal Carcinoma, T24 Bladder Cancer Cell Lines, or the MCF10A Non-Tumorigenic Epithelial Cell Line (72 h Treatment)a.